| Hyperlipidemia
Atorvaliq vs Zypitamag
Side-by-side clinical, coverage, and cost comparison for hyperlipidemia.Deep comparison between: Atorvaliq vs Zypitamag with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZypitamag has a higher rate of injection site reactions vs Atorvaliq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zypitamag but not Atorvaliq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Atorvaliq
Zypitamag
At A Glance
Oral
Daily
HMG-CoA reductase inhibitor
Oral
Daily
HMG-CoA reductase inhibitor
Indications
- Coronary heart disease
- Diabetes Mellitus, Non-Insulin-Dependent
- Heart failure
- Hyperlipidemia
- Hypercholesterolemia, Familial
- Hypertriglyceridemia
- Hyperlipidemia
Dosing
Coronary heart disease, Diabetes Mellitus Non-Insulin-Dependent, Heart failure, Hyperlipidemia, Hypertriglyceridemia 10 or 20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily; patients requiring LDL-C reduction >45% may start at 40 mg once daily.
Hypercholesterolemia, Familial (HeFH, pediatric >= 10 years) 10 mg once daily orally on an empty stomach; dosage range 10-20 mg once daily.
Hypercholesterolemia, Familial (HoFH, pediatric >= 10 years) 10-20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily.
Hyperlipidemia 2 mg to 4 mg orally once daily; recommended starting dose for moderate/severe renal impairment and end-stage renal disease on hemodialysis is 1 mg once daily (use alternative pitavastatin formulation), maximum 2 mg once daily; do not exceed 1 mg once daily with erythromycin; do not exceed 2 mg once daily with rifampin.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to atorvastatin or any excipients in ATORVALIQ
- Concomitant use of cyclosporine
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to pitavastatin or any excipients in ZYPITAMAG
Adverse Reactions
Most common (>=2%) Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Pancreatitis, fatigue, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, rhabdomyolysis, myositis, dizziness, peripheral neuropathy, cognitive impairment, depression, interstitial lung disease, angioneurotic edema, bullous rashes
Most common (>=2%) Myalgia, constipation, diarrhea, back pain, pain in extremity
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Abdominal discomfort, abdominal pain, dyspepsia, nausea, asthenia, fatigue, malaise, dizziness, hepatitis, jaundice, fatal and non-fatal hepatic failure, angioedema, muscle spasms, myopathy, rhabdomyolysis, hypoesthesia, peripheral neuropathy, cognitive impairment, insomnia, depression, erectile dysfunction, interstitial lung disease, lichen planus
Pharmacology
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a cholesterol precursor; it lowers plasma cholesterol and LDL levels by inhibiting hepatic cholesterol synthesis and increasing hepatic LDL receptor expression.
Pitavastatin is an HMG-CoA reductase inhibitor that blocks the conversion of HMG-CoA to mevalonate, a rate-limiting step in cholesterol biosynthesis, thereby upregulating LDL receptors, increasing LDL uptake by the liver, and reducing plasma LDL-C and VLDL levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Atorvaliq.
Zypitamag
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
No coverage data available for Atorvaliq.
Zypitamag
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
No coverage data available for Atorvaliq.
Zypitamag
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Atorvaliq.
No savings programs available for Zypitamag.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AtorvaliqView full Atorvaliq profile
ZypitamagView full Zypitamag profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.